In this study, we developed a computational approach centered on bioactive compounds from EVOO, aiming to investigate how their potential beneficial effects in AD may be related to the modulation of NRF2 (or its corresponding gene NFE2L2), a key regulator of antioxidant defenses against oxidative stress. Here, NFE2L2 is linked to Alzheimer disease.